Persistence with osteoporosis medication among newly-treated osteoporotic patients

Low persistence with osteoporosis medication is associated with higher fracture risk. Previous studies estimated that 1-year persistence with osteoporosis medication is low. Our aim was to study persistence with osteoporosis medication among patients with long-term follow-up (to 5 years). The InterA...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral metabolism 2013-09, Vol.31 (5), p.562-570
Main Authors: van Boven, Job F. M., de Boer, Pieter T., Postma, Maarten J., Vegter, Stefan
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Alendronate - administration & dosage
Alendronate - therapeutic use
Bone Density Conservation Agents - administration & dosage
Bone Density Conservation Agents - therapeutic use
Etidronic Acid - administration & dosage
Etidronic Acid - analogs & derivatives
Etidronic Acid - therapeutic use
Female
Humans
Male
Medication Adherence - statistics & numerical data
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Original Article
Orthopedics
Osteoporosis - drug therapy
Patient Compliance
Risedronate Sodium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Low persistence with osteoporosis medication is associated with higher fracture risk. Previous studies estimated that 1-year persistence with osteoporosis medication is low. Our aim was to study persistence with osteoporosis medication among patients with long-term follow-up (to 5 years). The InterAction Database (IADB) was used to analyze persistence of 8610 Dutch patients initiating osteoporosis drugs between 2003 and 2011. Drugs under study were alendronate, risedronate, ibandronate, etidronate, raloxifene and strontium ranelate. Cumulative persistence rates were calculated after different time frames (3 months–5 years) using survival analysis. Multivariate Cox proportional hazard analyses were used to identify determinants of non-persistence. Furthermore, switching rates of persistent patients who initiated bisphosphonate therapy were analyzed. Persistence with osteoporosis therapy was 70.7 % (95 % CI, 69.7–71.7), 58.5 % (95 % CI, 57.4–59.6 %), 25.3 % (95 % CI, 24.1–26.5) after 6 months, 1 and 5 years, respectively. Determinants associated with higher risk to non-persistence within the first year were daily dosing regimen [HR, 1.76 (95 % CI, 1.46–2.14)], age
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-013-0440-2